Cover Image

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

Yuan Wang,1 Guo-fang Hu,1 Qian-qian Zhang,1 Ning Tang,1 Jun Guo,2 Li-yan Liu,2 Xiao Han,2 Xia Wang,2 Zhe-hai Wang2 1School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, University of Jinan, 2Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People’s Rep...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wang Y (Author), Hu GF (Author), Zhang QQ (Author), Tang N (Author), Guo J (Author), Liu LY (Author), Han X (Author), Wang X (Author), Wang ZH (Author)
Format:	Book
Published:	Dove Medical Press, 2016-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib
by: Yin N, et al.
Published: (2020)

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
by: Hu GF, et al.
Published: (2016)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data
by: Chengcheng Gong, et al.
Published: (2022)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019)

Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients
by: Rikako Ueda, et al.
Published: (2022)

Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma
by: Yang Q, et al.
Published: (2022)

High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma
by: Lv W, et al.
Published: (2016)

c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer
by: Jingjing Yao, et al.
Published: (2022)

Gemcitabine and taxanes in metastatic breast cancer: a systematic review
by: Vinay Gudena, et al.
Published: (2008)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
by: Xu Zhu, et al.
Published: (2018)

Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells
by: Tormod Bjånes, et al.
Published: (2020)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
by: Kentaro Minami, et al.
Published: (2015)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
by: Long-fei Mao, et al.
Published: (2022)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
by: Cong Wang, et al.
Published: (2018)

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China
by: Kehui Meng, et al.
Published: (2024)

Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy
by: Nicolas Hohmann, et al.
Published: (2023)

A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS
by: Fan Z, et al.
Published: (2023)

Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy
by: Miguel Pereira-Silva, et al.
Published: (2024)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
by: Tianli Zhang, et al.
Published: (2022)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
by: Feng Shao, et al.
Published: (2018)

Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice
by: Kun Shi, et al.
Published: (2017)

Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
by: Andriana Inkoom, et al.
Published: (2020)

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
by: Immacolata Maietta, et al.
Published: (2022)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023)

Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation
by: Zhou X, et al.
Published: (2017)

Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012)

Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer
by: He C, et al.
Published: (2021)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
by: Gigin Lin, et al.
Published: (2018)

Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy: A Case Report and Review of the Literature
by: M. Wiesweg, et al.
Published: (2014)

Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment
by: Xiangming Kong, et al.
Published: (2022)

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
by: Shihui Bao, et al.
Published: (2021)

A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014)

Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]
by: Zhou X, et al.
Published: (2022)

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
by: Zhang J, et al.
Published: (2017)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023)